30 September 2019 | News
With this U.S. federal certification, Lucence can now receive patient specimens from the U.S. for testing with its LiquidHALLMARK®
image credit- shuttershock.com
International precision medicine firm Lucence Diagnostics has announced that it has received the Clinical Laboratory Improvement Amendments (CLIA) certification for its laboratory in Singapore from the U.S. Department of Health and Human Services’ Centers for Medicare & Medicaid Services.
With this U.S. federal certification, Lucence can now receive patient specimens from the U.S. for testing with its LiquidHALLMARK®, its flagship liquid biopsy blood test that simultaneously detects cancer-causing gene mutations and viruses present in 14 types of cancers to advance cancer diagnosis and treatment selection.
Dr Min-Han Tan, CEO and founder of Lucence, said, "This is a critical regulatory and commercial milestone for Lucence. We are proud to be the first regional laboratory in Southeast Asia to demonstrate compliance with U.S. federal regulatory standards, over and above our CAP and ISO 15189 Accreditations. We are glad to serve American doctors with our technological innovation in liquid biopsy to achieve better treatment selection for cancer patients."
These three internationally recognized credentials (CLIA, CAP and ISO15189) attest to Lucence’s compliance with the most comprehensive, rigorous and scientifically-endorsed standards of laboratory practice and underscore the company’s commitment to the highest global quality of cancer diagnostic services.